In a multi-institutional retrospective study of 1765 RCC tumors, the expression of FOLH1 strongly correlated with angiogenic gene expression in the tumor microenvironment.86 Additionally, patients whose tumor had higher FOLH1 expression tended to have longer treatment duration while on cabozantinib.86 These findings may support further studies of PSMA-based theranostics in combination with VEGF-targeted agents in RCC. The gene discussed is VEGFA; the disease is renal cell carcinoma.